Emotional Burden of Healthcare Professionals and Covid Infection 19 (Emocovid)

January 11, 2021 updated by: University Hospital, Limoges

Emotional Burden of Healthcare Professionals and the Epidemic Related to Covid Infection 19 -

COVID-19 ( known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)) has a highly polymorphic clinical presentation, ranging from pauci-symptomatic infection to severe, potentially complicated forms with acute respiratory distress syndrome or multisystemic organs failure. The picture may be initially severe, or it may progress in two stages, with worsening 7 to 10 days after the first symptoms with an overall case-fatality rate of 3 to 4%.

Its management is essentially symptomatic, as no antiviral treatment has so far demonstrated a clinical benefit in this condition.

In such a context, healthcare professionals assigned to COVID units will be faced with a heavy workload and emotional burden that could lead to psychological suffering or even burnout and its consequences.

We would therefore like to describe, using validated tools, the emotional evolution of the care workers at the Limoges University Hospital and the Esquirol University Hospital faced with this new pandemic infection. An initial and end-of-study evaluation of the caregivers will be carried out concerning their anxiety and depressive state, their personal capacity for resilience and their degree of empathy

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • ADULT
  • OLDER_ADULT
  • CHILD

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Health professional working

Description

Inclusion Criteria:

  • Health professional working in a COVID unit
  • For the qualitative study: 24 participant selected at random to be interviewed

Exclusion Criteria:

  • Refusal to participate

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
anxiety
Time Frame: 7 days,

Assessing the anxiety of health professionals using Anxiety Disorder Assessment (GAD-7) scale.

Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively.
7 days,
anxiety
Time Frame: 15 days,

Assessing the anxiety of health professionals using Anxiety Disorder Assessment (GAD-7) scale.

Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively.
15 days,
anxiety
Time Frame: 1 month

Assessing the anxiety of health professionals using Anxiety Disorder Assessment (GAD-7) scale.

Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively.
1 month
anxiety
Time Frame: 3 month

Assessing the anxiety of health professionals using Anxiety Disorder Assessment (GAD-7) scale.

Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively.
3 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Limoges

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

April 15, 2020

Primary Completion (ANTICIPATED)

February 15, 2021

Study Completion (ANTICIPATED)

June 15, 2021

Study Registration Dates

First Submitted

April 11, 2020

First Submitted That Met QC Criteria

April 15, 2020

First Posted (ACTUAL)

April 16, 2020

Study Record Updates

Last Update Posted (ACTUAL)

January 13, 2021

Last Update Submitted That Met QC Criteria

January 11, 2021

Last Verified

April 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 87RI20_0015/Emocovid

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Emotionnal Distress; COVID-19

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe